Physicians' Academy for Cardiovascular Education

Cost-effectiveness of a population genomic screening strategy for FH

Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis

Literature - Marquina C, Lacaze P, Tiller J et al. - Eur Heart J. 2021 Dec 1;42(45):4624-4634. doi: 10.1093/eurheartj/ehab702.

A cost-effectiveness study suggests that population genomic screening for FH in young adults could be cost-effective from a healthcare perspective and cost-saving from a societal perspective at testing costs that are feasible.

Introduction and methods


The prevalence of familial hypercholesterolemia (FH) is estimated to be 1:250 in the general population [1]. Early detection of FH is of utmost importance to provide appropriate preventive care as the process of atherosclerosis starts at birth. However, FH remains largely undiagnosed leading to a high burden of premature CVD morbidity and mortality [2,3]. An approach of opportunistic cholesterol screening and cascade testing, which is currently applied in most developed countries, is estimated to miss >90% of individuals with FH [4-7].

Aim of the study

This study investigated the cost-effectiveness of population genomic screening for FH in adults aged 18–40 years in Australia, in comparison with the current Australian standard-of-care for FH.

Model structure and population

Health and economic outcomes of the two different screening strategies for FH were compared using a decision analytic Markov model. The study population included all Australians aged 18-40 years (8,297,729 individuals). There were three different health states in the model: ‘Alive, no CHD’, ‘Alive, with CHD’, and ‘Dead’. The analysis was aimed to capture CHD morbidity and mortality in the FH population over a lifetime horizon.

Assumptions used in the model

The model used a heterozygous FH (HeFH) population prevalence of 1/250 [1]. It was further assumed that the current Australian detection strategy would detect 10% of individuals with HeFH in the modeled population [5]. For the strategy of population genomic screening to detect pathogenic variants in the LDLR/APOB/PCSK9 genes, the model assumed to detect 100% of individuals with HeFH.

The model assumed that 64.7% of the current FH population were receiving statin therapy, following a recent Australian study in patients with phenotypic FH [8]. In the population genomic screening strategy, the model assumed that 100% of individuals identified with FH received statin therapy after diagnosis.

Other variables that were applied in the model included coronary heart disease risk in the primary and secondary prevention population, effects of lipid-lowering treatment and utility weights (reflection of the perception of health by individuals). In scenario analyses, several parameters were varied including, but not limited to, FH prevalence, proportion of detected cases, proportion of patients treated with lipid-lowering therapy, effect sizes, and test costs.


The study included costs of population genomic screening, direct medical costs, costs of lipid-lowering treatment, and productivity costs due to the increased morbidity and mortality in

individuals with FH. A validated cost-adaptation method [9] was used to adapt results to eight high-income countries: France, Germany, Italy, The Netherlands, Slovenia, Spain, the UK, and the USA.


The primary outcome of this analysis was the incremental cost-effectiveness ratio (ICER), which was defined as cost per quality-adjusted life year (QALY). Secondary outcomes were years of life saved, and the number of CHD events prevented by the population genomic screening strategy.

Main results

Primary outcome: Incremental cost-effectiveness ratio (cost per QALY)

Secondary outcomes: Years of life saved, number of CHD events prevented and QALYs gained

Adaptation of results to other countries


A cost-effectiveness study suggests that population genomic screening for HeFH in young adults would be cost-effective from a healthcare perspective and cost-saving from a societal perspective if the costs per screening test would be ≤AU$250. The authors write that the per-test price of ≤AU$250 is feasible based on commercial targeted DNA sequencing panel costs. The current price per test is AU$1200 per sample.


Show references

Find this article online at Eur Heart J.

Share this page with your colleagues and friends: